Aduro BioTech (ADRO) Given a $15.00 Price Target at Oppenheimer
Oppenheimer set a $15.00 price objective on Aduro BioTech (NASDAQ:ADRO) in a research note released on Monday morning. The firm currently has a buy rating on the biotechnology company’s stock. Oppenheimer also issued estimates for Aduro BioTech’s Q1 2019 earnings at ($0.44) EPS, Q2 2019 earnings at ($0.47) EPS and Q3 2019 earnings at ($0.47) EPS.
Several other equities research analysts have also recently commented on the company. HC Wainwright set a $18.00 price target on Aduro BioTech and gave the stock a buy rating in a research note on Tuesday, October 17th. William Blair restated an outperform rating on shares of Aduro BioTech in a research note on Monday, October 2nd. Finally, BidaskClub cut Aduro BioTech from a hold rating to a sell rating in a research note on Saturday, December 9th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have given a buy rating to the stock. Aduro BioTech presently has an average rating of Buy and a consensus target price of $17.64.
Shares of Aduro BioTech (ADRO) opened at $8.10 on Monday. Aduro BioTech has a 52 week low of $6.01 and a 52 week high of $14.05.
Aduro BioTech (NASDAQ:ADRO) last released its quarterly earnings results on Tuesday, October 31st. The biotechnology company reported ($0.33) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.30) by ($0.03). Aduro BioTech had a negative return on equity of 39.28% and a negative net margin of 548.92%. The company had revenue of $3.79 million for the quarter, compared to analysts’ expectations of $4.04 million. During the same quarter last year, the company earned ($0.54) EPS. Aduro BioTech’s revenue for the quarter was up .0% compared to the same quarter last year. equities analysts anticipate that Aduro BioTech will post -1.28 EPS for the current year.
In other Aduro BioTech news, VP Blaine Templeman sold 2,884 shares of the stock in a transaction on Monday, September 18th. The stock was sold at an average price of $11.20, for a total value of $32,300.80. Following the completion of the transaction, the vice president now owns 58,834 shares in the company, valued at $658,940.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, COO Gregory W. Schafer sold 20,000 shares of the stock in a transaction on Monday, October 2nd. The stock was sold at an average price of $10.75, for a total value of $215,000.00. The disclosure for this sale can be found here. Insiders sold 251,142 shares of company stock valued at $2,337,732 in the last quarter. 6.60% of the stock is currently owned by company insiders.
Institutional investors have recently bought and sold shares of the business. JPMorgan Chase & Co. grew its holdings in Aduro BioTech by 283.7% in the second quarter. JPMorgan Chase & Co. now owns 372,348 shares of the biotechnology company’s stock valued at $4,244,000 after purchasing an additional 275,295 shares during the last quarter. Schwab Charles Investment Management Inc. grew its holdings in Aduro BioTech by 5.7% in the first quarter. Schwab Charles Investment Management Inc. now owns 145,112 shares of the biotechnology company’s stock valued at $1,560,000 after purchasing an additional 7,812 shares during the last quarter. Vanguard Group Inc. grew its holdings in Aduro BioTech by 2.1% in the first quarter. Vanguard Group Inc. now owns 2,382,916 shares of the biotechnology company’s stock valued at $25,617,000 after purchasing an additional 48,840 shares during the last quarter. PDT Partners LLC acquired a new stake in Aduro BioTech in the second quarter valued at $570,000. Finally, Artal Group S.A. grew its holdings in Aduro BioTech by 100.0% in the third quarter. Artal Group S.A. now owns 200,000 shares of the biotechnology company’s stock valued at $2,130,000 after purchasing an additional 100,000 shares during the last quarter. 45.19% of the stock is currently owned by institutional investors.
COPYRIGHT VIOLATION NOTICE: “Aduro BioTech (ADRO) Given a $15.00 Price Target at Oppenheimer” was posted by Watch List News and is the sole property of of Watch List News. If you are accessing this story on another publication, it was illegally copied and reposted in violation of U.S. and international copyright and trademark legislation. The legal version of this story can be read at https://www.watchlistnews.com/aduro-biotech-adro-given-a-15-00-price-target-at-oppenheimer/1765007.html.
About Aduro BioTech
Aduro Biotech, Inc is an immunotherapy company, which focuses on the discovery, development and commercialization of therapies that manage the treatment of various diseases, including cancer. The Company’s product candidates from its Live, Attenuated, Double-Deleted (LADD) Listeria monocytogenes, Stimulator of Interferon Genes Pathway Activator, and B-select monoclonal antibody platforms are designed to stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies, as well as other immunotherapies.
Receive News & Ratings for Aduro BioTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro BioTech and related companies with MarketBeat.com's FREE daily email newsletter.